Despite the benefit that the discovery of PSA provided in PCa detection, it remains an imperfect biomarker and there is room to add omics-based biomarkers to improve PCa detection. A number of cancer-related biomarkers of PCa have been identified that may play a role in early PCa detection or prognosis, including: PTEN, PI3K, PCA7 gene panel, PSGR, MME, PSCA, PCA3, TMPRSS2-ERG gene fusion, CD98, EPCA, CD276, prostate-specific membrane antigen (PSMA), caveolin-1, EN-1, and annexin A3 .